[go: up one dir, main page]

US20180177702A1 - Cosmetic composition having high dosage form stability - Google Patents

Cosmetic composition having high dosage form stability Download PDF

Info

Publication number
US20180177702A1
US20180177702A1 US15/739,000 US201615739000A US2018177702A1 US 20180177702 A1 US20180177702 A1 US 20180177702A1 US 201615739000 A US201615739000 A US 201615739000A US 2018177702 A1 US2018177702 A1 US 2018177702A1
Authority
US
United States
Prior art keywords
cosmetic composition
mel
dosage form
methylenedioxycinnamate
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/739,000
Other languages
English (en)
Inventor
Yu Jung Kim
Hyeon Chung Kim
Jae Won Yoo
Yong Jin Kim
Do Hoon Kim
Sung II Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority claimed from PCT/KR2016/005220 external-priority patent/WO2017003092A1/ko
Assigned to AMOREPACIFIC CORPORATION reassignment AMOREPACIFIC CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, DO HOON, KIM, HYEON CHUNG, KIM, YONG JIN, KIM, YU JUNG, PARK, SUNG IL, YOO, JAE WON
Publication of US20180177702A1 publication Critical patent/US20180177702A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Definitions

  • the present invention relates to a cosmetic composition in which a mannosylerythritol lipid is used as a stabilizer to enhance the dosage form stability of a composition including kojyl methylenedioxycinnamate used as an active ingredient for cosmetics.
  • a cosmetic composition includes various active ingredients to exhibit certain effects. Particularly, the skin is easily damaged by external stimuli because the skin is directly exposed to external environments.
  • kojyl methylenedioxycinnamate (Trade Name: Seletinoid GTM) is one of such materials, and particularly has excellent effects such as antiaging, antioxidant, and whitening effects.
  • the kojyl methylenedioxycinnamate is not easily dissolved in a composition due to strong crystallinity, and recrystallized or precipitated in a very short time even after dissolved in the composition, resulting in degraded skin absorption or texture in use of products.
  • these problems make it difficult to use the kojyl methylenedioxycinnamate as an active ingredient of a cosmetic composition even when the kojyl methylenedioxycinnamate has excellent effects.
  • the former has problems in that the solubility of the active ingredient inside a capsule is determined depending on the compatibility between polymers or the crystallinity of the polymers themselves, and a release rate of the active ingredient becomes very slow because crystals are independently formed in a polymer capsule in most cases, resulting in degraded efficiency in provision of the active ingredient.
  • the present inventors have selected various stabilizers and screened the stabilizers to select the best stabilizer capable of inhibiting crystallization of kojyl methylenedioxycinnamate, and found that crystal precipitation does not occur for a long time when it is determined whether crystals are generated after the stabilizer is prepared into a dosage form.
  • a cosmetic composition including kojyl methylenedioxycinnamate and a stabilizer.
  • a cosmetic composition which includes:
  • MEL mannosylerythritol lipid
  • R 1 to R 4 are as described in this specification.
  • the kojyl methylenedioxycinnamate may be included at a content of 0.05 to 0.25% by weight, based the total weight of the cosmetic composition.
  • mannosylerythritol lipid may be included at a content of 0.25 to 5.0% by weight, based the total weight of the cosmetic composition.
  • the kojyl methylenedioxycinnamate and the mannosylerythritol lipid may be included at a weight ratio of greater than 1:2.5 to 1:100.
  • the cosmetic composition according to the present invention serves to enhance stability of a dosage form including kojyl methylenedioxycinnamate, and thus can be useful in improving quality of products because problems regarding precipitation of crystals in conventional dosage forms are solved to prevent a decrease in texture in use caused due to a feeling of irritation by foreign substances when the crystals precipitate.
  • the function of the kojyl methylenedioxycinnamate can be maximized to enhance skin whitening and skin elasticity and inhibit formation of wrinkles, thereby preventing skin ageing.
  • FIG. 1 is an image of a cosmetic composition prepared in Comparative Example 1 taken with time using an optical microscope ( ⁇ 500) and a polarizing microscope ( ⁇ 500).
  • FIG. 2 is an image of a cosmetic composition prepared in Example 1 taken with time using an optical microscope ( ⁇ 500) and a polarizing microscope ( ⁇ 500).
  • a novel cosmetic composition capable of fundamentally blocking crystal formation and precipitation from occurring in the cosmetic composition including kojyl methylenedioxycinnamate as an active ingredient.
  • the kojyl methylenedioxycinnamate of Formula 1 is named 2-((3E)-4(2H,3H-benzo[3,4-d]-1,3-dioxolan-5- yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one according to the IUPAC system, and commercially sold on the market as the trade name ‘Seletinoid GTM’.
  • the kojyl methylenedioxycinnamate has various skin effects such as antiaging, whitening, and antioxidant effects, and has been used as an active ingredient of the cosmetic composition in various dosage forms.
  • a compound is not easily dissolved in the composition due to strong crystallinity and problems such as crystallization and crystal precipitation may be caused with time even after the compound is dissolved in the composition, the dosage form stabilization may be seriously degraded, and the texture in use may be lowered.
  • a mannosylerythritol lipid (hereinafter referred to as ‘MEL’) is used as a stabilizer in the present invention to prevent crystallization of the compound.
  • the MEL is represented by the following Formula 2:
  • R 1 and R 2 are the same or different from each other, and each independently a C2 to C24 aliphatic acyl group, and R 3 and R 4 are the same or different from each other, and each independently an acetyl group or hydrogen.
  • R 1 and R 2 may be the same or different from each other, and each independently a C6 to C18 aliphatic acyl group, wherein the aliphatic acyl group is represented by —C( ⁇ O)—(CH 2 ) n —CH 3 .
  • n may be in a range of 3 to 15.
  • the MEL may be any one selected from MEL-A, MEL-B, MEL-C, and MEL-D, which are defined by the following Formula 3:
  • R 5 and R 6 are the same or different from each other, and are an acetyl group or hydrogen, and n or m is an integer ranging from 6 to 10.
  • the MEL-A is a compound in which R 5 and R 6 are an acetyl group in Formula
  • the MEL-B is a compound in which R 5 is hydrogen and R 6 is an acetyl group
  • the MEL-C is a compound in which R 5 is an acetyl group and R 6 is a hydrogen
  • the MEL-D is a compound in which both R 5 and R 6 are hydrogen.
  • the MEL is one of biosurfactants having a surface activity.
  • a biosurfactant may be prepared from microorganisms. Therefore, the biosurfactant has a skin-protecting effect because the biosurfactant is high biodegradable, has low toxicity, is not harmful to the human body skin, and has an excellent moisturizing ability. Also, the biosurfactant is a material that has a degree of surface activity corresponding to those of chemically synthetic surfactants used in the related art because the biosurfactant has a minimum surface tension of 29 dyne/cm and a critical micelle concentration (CMC) of 15 ⁇ M (10 mg/L).
  • CMC critical micelle concentration
  • the MEL is not particularly limited in the present invention, and may be performed as known in the related art.
  • the MEL may be obtained from one or more corresponding microbes selected from Candida sp., Torulopsis sp., Pseudomonas sp., Bacillus sp., Alcaligenes sp., Acinetobacter sp., Ustilago sp., Rhodococcus sp., and the like.
  • the MEL of Formula 2 when used as the stabilizer together with the kojyl methylenedioxycinnamate of Formula 1, the crystallization and crystal precipitation caused due to low dosage form stability of the kojyl methylenedioxycinnamate may be prevented.
  • Such dosage form stability exhibits the same results even at low, room and high temperatures.
  • each of MEL, ethyl alcohol, polysorbate 20, diethoxyethyl succinate and glyceryl/polyglyceryl-6-isostearate/behenate ester was used together with the kojyl methylenedioxycinnamate to prepare a dosage form, and the crystallization tendency of such components was checked. As a result, it was confirmed that no crystallization occurred with time only in the composition including the MEL, but the crystallization occurred seriously when the other components were used.
  • the MEL has an advantage in that kojyl methylenedioxycinnamate is included as the active ingredient at a high concentration of up to 0.25% by weight when the MEL is used to enhance the dosage form stability.
  • the crystallization refers to the stability of a dosage form.
  • the content of the active ingredient, the content of the MEL, and the content ratios of the active ingredient and MEL may be important parameters associated with the stability.
  • the cosmetic composition of the present invention includes the koj yl methylenedioxycinnamate at 0.05 to 0.25% by weight, preferably 0.05 to 0.15% by weight, based on the total weight of the cosmetic composition.
  • the content of the kojyl methylenedioxycinnamate is less than this content range, effects obtained through the use of the kojyl methylenedioxycinnamate, that is, antiaging, whitening and antioxidant effects may not be secured.
  • the content of the kojyl methylenedioxycinnamate is greater than this content range, the crystallization may occur due to degraded stability.
  • the MEL is used at content of 0.25 to 5.0% by weight, preferably 0.25 to 2.0% by weight, based on the total weight of the cosmetic composition.
  • content of the MEL is less than this content range, stabilization of the kojyl methylenedioxycinnamate may not be achieved, which leads to crystallization.
  • content of the MEL is greater than this content range, it is uneconomical because there is no difference in effects. Therefore, the MEL is properly used within this content range.
  • the weight ratio of the MEL to the kojyl methylenedioxycinnamate may be possibly greater than 1:2.5.
  • the kojyl methylenedioxycinnamate and the MEL are used at a weight ratio of greater than 1:2.5 to 1:100, more preferably a weight ratio of 1:3 to 1:20.
  • the cosmetic composition including the kojyl methylenedioxycinnamate and the MEL provides antiaging, whitening and antioxidant effects when applied onto the skin, thereby preventing skin aging through enhancing skin whitening and skin elasticity and inhibiting wrinkle formation.
  • the cosmetic composition according to the present invention may include a cosmetologically or dermatologically acceptable medium or base material so that it can be prepared into dosage forms.
  • components included in the cosmetic composition of the present invention components generally used in the cosmetic composition.
  • the components may include an oily component, a moisturizing agent, a softening agent, a surfactant, an organic and inorganic pigment, an organic powder, a UV absorbent, a preservative, an antifoaming agent, a thickening agent, a disinfectant, an antioxidant, a plant extract, a pH control agent, an alcohol, a coloring agent, a flavoring agent, a blood flow stimulant, a cooling agent, an antihidrotic agent, and the like.
  • the cosmetic composition of the present invention may also be prepared into any dosage forms generally prepared in the related art.
  • the cosmetic composition may be prepared into dosage forms such as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleansing cream, an oil, a powder foundation, an emulsion foundation, a wax foundation, and a spray, but the present invention is not limited thereto.
  • the cosmetic composition may be prepared into dosage forms such as an emulsifying toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, and a powder.
  • dosage forms such as an emulsifying toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, and a powder.
  • the dosage form of the present invention is a paste, a cream, or a gel
  • an animal oil a vegetable oil, wax, paraffin, starch, tragacanth, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, or zinc oxide may be used as the carrier component.
  • the dosage form of the present invention is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as the carrier component.
  • the cosmetic composition may further include a propellant such as chlorofluorohydrocarbon, propane, butane, or dimethyl ether.
  • the carrier component may include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, glycerin, carbomer, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, glycerol aliphatic ester, caprylic/capric triglycerides, hydrogenated polydecene, cetearyl glucoside, sorbitan stearate, polyethylene glycol, cetearyl alcohol, and the like.
  • the dosage form of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth may be used as the carrier component.
  • the dosage form of the present invention is a surfactant-containing cleansing cream
  • fatty alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinate monoester, isethionate, an imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkyl amido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanol amide, vegetable oil, a lanolin derivative, or ethoxylated glycerol fatty acid ester may be used as the carrier component.
  • the cosmetic composition according to the present invention may be an emulsion, that is, an emulsified dosage form.
  • the emulsion is a dosage form system most typically used in the field of cosmetics, and refers to a system in which an oily phase and an aqueous phase are uniformly dispersed using an emulsification technique. Such an emulsion may be prepared into various forms, depending on the compositions having a continuous phase.
  • a water-in-oil (W/O), oil-in-water (O/W), water-in-oil-in-water (W/O/W), or oil-in-water-in-oil(O/W/O) emulsion is possible.
  • the shapes of the emulsion are not particularly limited.
  • a polyol is used together with water in the aqueous phase, and an oil is used in the oily phase.
  • various additives, stabilizers, surfactants, UV absorbents, and the like may be added to each phase.
  • the water used in the aqueous phase is distilled water.
  • deionized distilled water is used.
  • the water is used as the balance so that the total weight of the composition satisfies 100% by weight.
  • the polyol used in the aqueous phase is used for the purpose of moisturizing, and has a refractive index ranging from 1.3 to 1.5.
  • one selected from the group consisting of glycerin, propylene glycol, butylene glycol, glycerin, erythritol, xylitol, maltitol glycerin, sorbitol, polyglycerin, polyethylene glycol, pentanediol, isoprene glycol, and a combination thereof is used as the polyol.
  • the polyol may be used at a content of 0.1 to 20.0% by weight, based on the total weight of the composition.
  • the oil used in the oily phase is not particularly limited in the present invention.
  • any oils may be used as long as they are generally used in the related art.
  • aqueous and oily phases may further include a thickening agent.
  • a thickening agent sodium polyacrylate copolymers, carbomers, crosslinked or non-crosslinked acrylic polymers, particularly crosslinked polyacrylic acids as a multivalent functional base, for example, the trade name “CARBOPOL” commercially available from Goodrich Corp., cellulose derivatives, for example, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, sodium salts of carboxymethyl cellulose, cetyl stearyl alcohol, a mixture of oxyethylenated cetyl stearyl alcohol containing 33 mol ethylene oxide, guar gum, xanthan gum, and a combination thereof may be used as the thickening agent.
  • the thickening agent may be used at a content of 0.01 to 10.0% by weight, based on the total weight of the composition.
  • At least one of the aqueous and oily phases may further include a surfactant.
  • additives as known in the related art, such as a water-/oil-soluble physiologically active component, a moisturizing agent, a preservative, a pH regulator, fatty acid, an emulsifying agent, an antioxidant, a sunscreen, a pigment, a dye, a flavoring agent, a stabilizer, and the like, may be additionally added, when necessary.
  • the types and contents of the additives may be properly selected by a person having ordinary skill in the art.
  • An emulsion dosage form is prepared into various forms by preparing an aqueous phase including water as a continuous phase, preparing an oily phase including an oil as a continuous phase, and varying a mixing order of the aqueous and oily phases. Specifically, the aqueous phase is heated at 50 to 90° C., preferably 60 to 80° C., and the oily phase is heated at 50 to 80° C., preferably 65 to 75° C. so that the other components are sufficiently dissolved in the oil.
  • the stirring is performed at a rotary speed of 2,000 to 4,000 rpm, preferably 3,000 rpm for 3 to 10 minutes in a vacuum emulsifier tank using a homomixer.
  • the kojyl methylenedioxycinnamate and the MEL according to the present invention may be added to either the aqueous phase or oily phase, or may be added after an emulsion is finally prepared.
  • the kojyl methylenedioxycinnamate and the MEL may be added after the aqueous phase and the oily phase are mixed.
  • the cosmetic composition thus prepared may have effects of improving stabilization of the dosage form and enhancing the texture in use because the cosmetic composition maximizes the effective function of kojyl methylenedioxycinnamate and prevents crystallization from occurring even after prepared into a dosage form.
  • Emulsions for skin care were prepared using the compositions presented in the following Table 1.
  • components 1 to 4 were mixed, and dissolved at 70° C. to prepare an aqueous phase.
  • components 5 to 11 were dissolved at 70° C. to prepare an oily phase.
  • the oily phase was added to the aqueous phase, and primarily emulsified while stirring using a homomixer.
  • component 12 was added thereto to increase a viscosity of the mixture.
  • bubbles were removed, components 13 and 14 were added thereto, and the resulting mixture was then cooled to prepare an emulsion composition.
  • SurfMellow BBG manufactured by Toyobo Co., Ltd.
  • Example Comparative Comparative Comparative Comparative Comparative Comparative Comparative Components (% by weight) 1 Example 1 Example 2 Example 3 Example 4 Example 5 Aqueous phase 1. Purified water Up to 100 Up to 100 Up to 100 Up to 100 Up to 100 Up to 100 Up to 100 Up to 100 2. Glycerin 8 8 8 8 8 3. Butylene glycol 4 4 4 4 4 4. Carbomer 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Oily phase 5. Caprylic/capric 8 8 8 8 8 triglyceride 6. Hydrogenated 5 5 5 5 5 5 5 5 5 5 polydecene 7. Cetearyl glucoside 1.5 1.5 1.5 1.5 1.5 8. Sorbitan stearate 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 9. Cetearyl alcohol 1 1 1 1 1 10.
  • Example Comparative Comparative Comparative Comparative Comparative 1 Example 1
  • Example 2 Example 3
  • Example 4 Example 5 Immediately X X X X X X after preparation Week 3 X ⁇ ⁇ ⁇ ⁇ ⁇ Week 10 X ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
  • FIGS. 1 and 2 show the results of checking formation of crystals and observing the size of the crystals for the respective compositions immediately after the preparation and on weeks 3 and on weeks 10 using an optical microscope ( ⁇ 500) and a polarizing microscope ( ⁇ 500).
  • Example 1 shown in FIG. 2 was maintained in a stable state without forming the crystals even after 10 weeks of the preparation because the MEL was used in the composition.
  • emulsion compositions were prepared in the same manner as in the composition of Example 1, and precipitation tests were performed on the emulsion compositions.
  • the content of the component was adjusted to 100% by weight by varying the content of purified water.
  • Such a content of the MEL means a content of the MEL, when the content of the kojyl methylenedioxycinnamate is 0.1% by weight.
  • a test was performed on the content ratios of the MEL and kojyl methylenedioxycinnamate.
  • emulsion compositions were prepared in the same manner as in the composition of Example 1, and precipitation tests were performed on the emulsion compositions.
  • the content of the component was adjusted to 100% by weight by varying the content of purified water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
US15/739,000 2015-06-30 2016-05-18 Cosmetic composition having high dosage form stability Abandoned US20180177702A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20150092713 2015-06-30
KR10-2015-0092713 2015-06-30
KR1020160060155A KR102552729B1 (ko) 2015-06-30 2016-05-17 높은 제형 안정성을 갖는 화장료 조성물
KR10-2016-0060155 2016-05-17
PCT/KR2016/005220 WO2017003092A1 (ko) 2015-06-30 2016-05-18 높은 제형 안정성을 갖는 화장료 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/005220 A-371-Of-International WO2017003092A1 (ko) 2015-06-30 2016-05-18 높은 제형 안정성을 갖는 화장료 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/290,210 Continuation US10792238B2 (en) 2015-06-30 2019-03-01 Cosmetic composition having high dosage form stability

Publications (1)

Publication Number Publication Date
US20180177702A1 true US20180177702A1 (en) 2018-06-28

Family

ID=57811018

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/739,000 Abandoned US20180177702A1 (en) 2015-06-30 2016-05-18 Cosmetic composition having high dosage form stability
US16/290,210 Active US10792238B2 (en) 2015-06-30 2019-03-01 Cosmetic composition having high dosage form stability

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/290,210 Active US10792238B2 (en) 2015-06-30 2019-03-01 Cosmetic composition having high dosage form stability

Country Status (6)

Country Link
US (2) US20180177702A1 (zh)
JP (1) JP6770007B2 (zh)
KR (1) KR102552729B1 (zh)
CN (1) CN107920975B (zh)
AU (1) AU2016287136B2 (zh)
TW (1) TWI725031B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514805B2 (en) 2022-05-10 2026-01-06 Amorepacific Corporation Composition for suppressing skin irritation or inhibiting sebum secretion

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240165495A (ko) 2023-05-15 2024-11-25 (주)아모레퍼시픽 높은 제형 안정성을 가지는 에멀전 제형 및 이의 제조 방법
KR102839555B1 (ko) * 2024-10-04 2025-07-29 한국콜마주식회사 자외선 차단제의 용해 안정성을 향상시킨 화장료 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100482668B1 (ko) * 2002-06-22 2005-04-13 주식회사 태평양 히드록시 피라논 유도체 및 이의 제조방법
KR100494535B1 (ko) 2003-02-24 2005-06-10 주식회사 태평양 히드록시 피라논 유도체를 함유하는 피부 미백용 외용제조성물
JP4675033B2 (ja) 2003-08-21 2011-04-20 広島県 血小板凝集抑制剤及びヒスタミン遊離抑制剤
WO2007060956A1 (ja) 2005-11-25 2007-05-31 Toyo Boseki Kabushiki Kaisha バイオサーファクタントを含有するスキンケア化粧料および肌荒れ改善剤
KR100704468B1 (ko) 2006-04-20 2007-04-09 (주)아모레퍼시픽 히드록시 피라논 유도체 및 이의 제조방법
JP4982822B2 (ja) 2006-08-11 2012-07-25 東洋紡績株式会社 バイオサーファクタントを有効成分とする賦活化剤
EP2074985B1 (en) 2006-08-11 2013-07-03 Toyobo Co., Ltd. Activator including biosurfactant as active ingredient, mannosyl erythritol lipid, and production method thereof
AU2008254925A1 (en) 2007-05-15 2008-11-27 Puretech Ventures Methods and compositions for treating skin conditions
BRPI0819218A2 (pt) 2007-11-05 2015-05-05 Puretech Ventures Métodos, estojos e composições para administração de compostos farmacêuticos
JP2009167159A (ja) 2007-12-21 2009-07-30 Toyobo Co Ltd バイオサーファクタントを含有する化粧品組成物
JP2009149566A (ja) * 2007-12-21 2009-07-09 Toyobo Co Ltd バイオサーファクタントを含有する化粧品組成物
JP2009201478A (ja) 2008-02-29 2009-09-10 Idemitsu Kosan Co Ltd マンノシルエリスリトールリピッドの回収方法
JP2009275017A (ja) 2008-05-16 2009-11-26 Toyobo Co Ltd バイオサーファクタント含有水中油型乳化化粧品組成物
JP2010018558A (ja) * 2008-07-11 2010-01-28 Toyobo Co Ltd バイオサーファクタントを含有する化粧品組成物
AU2008363987B2 (en) * 2008-11-11 2012-10-11 Colgate Palmolive Company Composition with a color marker
JP5447967B2 (ja) * 2009-09-04 2014-03-19 独立行政法人産業技術総合研究所 バイオサーファクタントからなる逆ベシクル
JP5639067B2 (ja) 2009-09-29 2014-12-10 東洋紡株式会社 化粧料用顔料及びその製造方法並びにその化粧料用顔料を含有する化粧料
JP2011105607A (ja) 2009-11-12 2011-06-02 Toyobo Co Ltd バイオサーファクタントを有効成分とするアレルギー反応遅発相抑制剤
JP5707062B2 (ja) 2010-06-15 2015-04-22 ポーラ化成工業株式会社 皮膚外用組成物
JP5693245B2 (ja) 2011-01-06 2015-04-01 花王株式会社 皮膚外用剤
KR101866923B1 (ko) 2011-09-02 2018-06-15 (주)아모레퍼시픽 피부 미백 효과를 나타내는 신규 코지산 유도체
KR101853718B1 (ko) * 2011-09-02 2018-05-03 (주)아모레퍼시픽 코지산 유도체 제조 방법
JP6219029B2 (ja) 2012-11-19 2017-10-25 ポーラ化成工業株式会社 Ｏ／ｗ／ｏ型乳化剤型の皮膚外用剤
JP2014181208A (ja) 2013-03-19 2014-09-29 Toyobo Co Ltd 皮膚刺激緩和剤
KR102066108B1 (ko) 2013-11-29 2020-01-15 (주)아모레퍼시픽 페닐링을 가지는 2종 화합물을 포함하는 화장료 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514805B2 (en) 2022-05-10 2026-01-06 Amorepacific Corporation Composition for suppressing skin irritation or inhibiting sebum secretion

Also Published As

Publication number Publication date
AU2016287136A1 (en) 2018-02-15
TW201700089A (zh) 2017-01-01
TWI725031B (zh) 2021-04-21
CN107920975A (zh) 2018-04-17
KR20170003383A (ko) 2017-01-09
US10792238B2 (en) 2020-10-06
JP6770007B2 (ja) 2020-10-14
KR102552729B1 (ko) 2023-07-06
JP2018526331A (ja) 2018-09-13
CN107920975B (zh) 2021-01-08
US20190192412A1 (en) 2019-06-27
AU2016287136B2 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP6010418B2 (ja) 乳化組成物
US8992956B2 (en) Cosmetic composition stabilized higher oily part
US20120189675A1 (en) Skin External Preparations
KR101867847B1 (ko) 재결정 입자를 갖는 수중유 유화 조성물 및 이를 포함하는 화장료 조성물
US20180344587A1 (en) Cosmetic composition with multiple emulsion formulation having lamellar liquid crystal structure
KR101492290B1 (ko) 베시클 조성물, 및 피부 외용제
CN114129462B (zh) 低粘度水包油包水型多重乳浊液化妆品组合物
US9757322B2 (en) Liquid cosmetic
ES2639289T3 (es) Cosmético de protección solar emulsionado tipo aceite en agua
CN101827578B (zh) 反相囊泡组合物
US10792238B2 (en) Cosmetic composition having high dosage form stability
KR20180023537A (ko) 고함량의 세라마이드를 포함하는 수중유형 에멀젼 조성물 및 이를 포함하는 화장료 조성물
CA2106566A1 (en) Stable multiple emulsions
CN106606424B (zh) 一种含菊粉月桂基氨基甲酸酯和脂肪醇的液晶体系的制备和应用
KR101682984B1 (ko) 제니스테인 메틸 에테르-함유 나노리포좀, 이의 제조 방법 및 이를 포함하는 화장용 조성물
EP4190404A1 (en) Water-in-oil-in-water type emulsion cosmetic composition and method for manufacturing thereof
US20240216231A1 (en) High-hardness liquid crystal cosmetic composition having elastic texture and method for preparing same
US20200345594A1 (en) Gelatinous composition and production method therefor
WO2017003092A1 (ko) 높은 제형 안정성을 갖는 화장료 조성물
US20250057746A1 (en) Oil-in-water type d-phase emulsion composition with excellent emulsion stability
WO2024134242A1 (en) Oil-in-water emulsion
WO2025134804A1 (ja) 化粧料
KR20150143068A (ko) 비오카닌 ａ를 함유한 라멜라형 비수계 액정상 캡슐기재 조성물 및 이를 이용한 화장료 조성물
HK1139601B (zh) 囊泡组合物及皮肤外用剂

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMOREPACIFIC CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, YU JUNG;KIM, HYEON CHUNG;YOO, JAE WON;AND OTHERS;REEL/FRAME:044470/0192

Effective date: 20171214

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION